Immunocore Holdings plc 10-K

Item 9A. Controls and Procedures 119 Table of Contents Disclosure Controls and Procedures We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2023. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2023, our disclosure controls and procedures were effective. Management’s Annual Report on Internal Control Over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Exchange Act Rules 13a-15(f ) and 15d-15(f ) define this as a process designed by, or under the supervision of, our Chief Executive Officer and our Chief Financial Officer and effected by the Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. Due to its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Furthermore, projections of any evaluation of the effectiveness of internal controls to future periods may prove invalid due to changes in our circumstances and the risk that compliance with policies, procedures and controls is not sustained. Management has assessed the effectiveness of internal control over financial reporting as of December 31, 2023 based on the Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) . Based on this assessment, management has concluded that our internal control over financial reporting as of December 31, 2023 was effective. The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by Deloitte LLP, an independent registered public accounting firm, as stated in their report that is included herein. Our independent registered public accountant, Deloitte LLP, who audited the consolidated financial statements as of and for the year ended December 31, 2023 included in this annual report, have audited the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023. Deloitte LLP’s report is included below. Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Immunocore Holdings plc: Opinion on Internal Control Over Financial Reporting We have audited the internal control over financial reporting of Immunocore Holdings plc and subsidiaries (the “Company”) as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2023, of the Company and our report dated February 28, 2024 expressed an unqualified opinion on those financial statements and included an explanatory paragraph regarding the Company’s change in reporting framework. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. 120 Table of Contents Definition and Limitations of Internal Control Over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ Deloitte LLP Cambridge, United Kingdom February 28, 2024 Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Item 9B. Other Information Insider Trading Arrangements During the three months ended December 31, 2023, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Not applicable PART III Item 10. Directors, Executive Officers and Corporate Governance The information required by this item is incorporated by reference to our Proxy Statement for our 2024 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023. We have adopted a Code of Business Conduct and Ethics that is applicable to all of our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, to the principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions from a provision of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. The Code of Business Conduct and Ethics is available on our website at https://ir.immunocore.com/corporate-governance/document-charters. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report and is not incorporated by reference herein. Item 11. Executive Compensation The information required by this item is incorporated by reference to our Proxy Statement for our 2024 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters The information required by this item is incorporated by reference to our Proxy Statement for our 2024 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023. 121 Table of Contents Item 13. Certain Relationships and Related Transactions, and Director Independence The information required by this item is incorporated by reference to our Proxy Statement for our 2024 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023. Item 14. Principal Accountant Fees and Services The information required by this item is incorporated by reference to our Proxy Statement for our 2024 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2023. PART IV Item 15. Exhibits and Financial Statement Schedules Incorporation by Reference Exhibit Number Description Schedule/ Form File Number Exhibit Filing Date 3.1 Articles of Association of Immunocore Holdings plc 20-F 001-39992 1.1 March 25, 2021 4.1 Deposit Agreement 20-F 001-39992 2.2 March 25, 2021 4.2 Form of American Depositary Receipt (included in Exhibit 2.2) 20-F 001-39992 2.3 March 25, 2021 4.3 Description of Registered Securities 20-F 001-39992 2.4 March 25, 2021 10.1 Subscription Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated February 3, 2021 F-1/A 333-252166 4.3 February 3, 2021 10.2† Research Collaboration and License Agreement, dated as of June 14, 2013, by and among the Registrant, Genentech, Inc. and F. Hoffman-La Roche Ltd, as amended on September 27, 2016 F-1 333-252166 10.5 January 15, 2021 10.3† License Agreement, dated as of September 27, 2016, between the Registrant and Genentech, Inc. F-1 333-252166 10.8 January 15, 2021 10.4† License and Collaboration Agreement, dated as of November 15, 2018, by and among the Registrant, Genentech, Inc. and F. Hoffman-La Roche Ltd. F-1 333-252166 10.9 January 15, 2021 10.5 Amended and Restated Global Access Commitments Agreement, dated as of March 2, 2020, between the Registrant and the Bill & Melinda Gates Foundation F-1 333-252166 10.11 January 15, 2021 122 Table of Contents 10.6† First Amendment to the Amended and Restated Global Access Commitments Agreement, dated as of February 3, 2021, between the Registrant and the Bill & Melinda Gates Foundation F-1/A 333-252166 10.12 February 3, 2021 10.7 Lease, dated as of March 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP F-1 333-252166 10.13 January 15, 2021 10.8 Lease, dated as of December 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP F-1 333-252166 10.14 January 15, 2021 10.9 Lease, dated as of March 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP F-1 333-252166 10.15 January 15, 2021 10.10† Assignment and Exclusive License, dated as of January 28, 2015, between the Registrant and Adaptimmune Limited F-1 333-252166 10.16 January 15, 2021 10.11# Employment Agreement between the Registrant and Bahija Jallal, Ph.D., dated January 29, 2021 F-1 333-252166 10.18 January 15, 2021 10.12#* Employment Agreement between the Registrant and Brian Di Donato, dated January 29, 2021 10.13#* Employment Agreement between the Registrant and David Berman, MD., Ph.D., dated January 29, 2021 10.14#* Employment Agreement between the Registrant and Tina St Leger, dated August 2, 2021 10.15 Form of Deed of Indemnity between the Registrant and each of its directors F-1 333-252166 10.1 January 15, 2021 123 Table of Contents 10.16 Form of Deed of Indemnity between the Registrant and each of its executive officers F-1 333-252166 10.2 January 15, 2021 10.17 Immunocore Holdings plc 2021 Equity Incentive Plan. and Non-Employee Sub Plan to the Immunocore Holdings plc 2021 Equity Incentive Plan 20-F 001-39992 4.20 March 25, 2021 10.18 Registration Rights Agreement, dated July 15, 2022, by and among Immunocore Holdings plc and the investors party thereto 6-K 001-39992 99.2 July 20, 2022 10.19 Sales Agreement, dated as of September 9, 2022, by and between the Company and Jefferies LLC 6-K 001-39992 1.1 September 9, 2022 10.20 Loan Agreement, dated as of November 8, 2022, among Immunocore Limited, as Borrower, the Registrant, certain additional Credit Parties and Guarantors party thereto, BioPharma Credit PLC, as Collateral Agent, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP as Lenders 6-K 001-39992 99.4 November 9, 2022 16.1 Letter from KPMG LLP, dated March 1, 2023 20-F 001-39992 16.1 March 1, 2023 21.1* Subsidiaries of the Registrant 23.1* Consent of Deloitte LLP 23.2* Consent of KPMG LLP 24.1* Power of Attorney (incorporated by reference to the signature pages of this Annual Report on Form 10-K). 31.1* Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Certification by the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 97.1* Immunocore Holdings plc Incentive Compensation Recoupment Policy 124 Table of Contents 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) * Filed herewith. ** This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. † Certain portions of this exhibit (indicated by asterisks) have been redacted in accordance with Regulation S-K, Item 601(b)(10). # Indicates a management contract or any compensatory plan, contract or arrangement. Item 16. Form 10-K Summary None. SIGNATURES Pursuant to the requirements of Section 13 and 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOCORE HOLDINGS PLC By: /s/ Bahija Jallal Bahija Jallal, Ph.D. Chief Executive Officer ( Principal Executive Officer) Date: February 28, 2024 125 Table of Contents POWER OF ATTORNEY Each of the undersigned officers and directors of Immunocore Holdings plc, hereby constitutes and appoints Bahija Jallal and Brian Di Donato, their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on February 28, 2024 on behalf of the registrant and in the capacities indicated. SIGNATURE TITLE DATE /s/ Bahija Jallal, Ph.D. Chief Executive Officer and Director (Principal Executive Officer) February 28, 2024 Bahija Jallal, Ph.D. /s/ Brian Di Donato Chief Financial Officer (Principal Financial Officer) February 28, 2024 Brian Di Donato /s/ John Goll SVP, Finance and Chief Accounting Officer (Principal Accounting Officer) February 28, 2024 John Goll /s/ Professor Sir John Bell Chairman of the Board of Directors February 28, 2024 Professor Sir John Bell /s/ Travis Coy Director February 28, 2024 Travis Coy /s/ Roy S. Herbst, M.D., Ph.D. Director February 28, 2024 Roy S. Herbst, M.D., Ph.D. /s/ Siddharth Kaul Director February 28, 2024 Siddharth Kaul /s/ Robert Perez Director February 28, 2024 Robert Perez /s/ Kristine Peterson Director February 28, 2024 Kristine Peterson /s/ Professor Sir Peter Ratcliffe Director February 28, 2024 Professor Sir Peter Ratcliffe 126 Table of Contents INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 1147 ) F-2 Report of Independent Registered Public Accounting Firm (PCAOB ID 1118 ) F-4 Consolidated Balance Sheets as of December 31, 2023 and 2022 F-5 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023, 2022 and 2021 F-6 Consolidated Statements of Shareholders’ Equity for the Years Ended December 31, 2023, 2022 and 2021 F-7 Consolidated Statements of Cash Flows for the Years Ended December 31, 2023, 2022 and 2021 F-8 Notes to the Consolidated Financial Statements F-9 F-1 Table of Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the shareholders and the Board of Directors of Immunocore Holdings plc Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Immunocore Holdings plc and subsidiaries (the “Company”) as of December 31, 2023, the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows, for the year ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2024, expressed an unqualified opinion on the Company’s internal control over financial reporting. Change in Reporting Framework As discussed in Note 1 to the financial statements, the Company has changed its reporting framework from International Financial Reporting Standards as issued by the International Accounting Standards Board to accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. Product revenue, net – Deductions for government rebates — Refer to Notes 2 and 3 to the financial statements Critical Audit Matter Description As more fully disclosed in the Significant Accounting Policies note to the financial statements, the Company recognizes revenue for product sales at the net sales price, which includes deductions for which reserves are established. These deductions include rebates, chargebacks, levies, other customer fees and product returns. Government rebates are provided to Medicare, state Medicaid programs and similar programs in Europe. Management is required to make significant assumptions and judgments to estimate the government rebate claims related to sales in the respective geographies. These assumptions and judgements include: (1) pricing in geographies where negotiations are ongoing with the respective governments; (2) amounts where the government has the potential to clawback additional costs based on volume of sales, government budgets or through renegotiation of pricing; and (3) future claims yet to be received, related to products sold in the reporting period. F-2 Table of Contents These estimates include consideration of internal forecasts of the patient and distributor mix, information obtained from historic claims received and other industry data, and external health coverage statistics. We identified the deductions for government rebates as a critical audit matter given the complexity involved in determining the significant assumptions and judgments used in estimating the anticipated government rebate claims, which in turn led to a high degree of auditor professional judgment and increased extent of audit effort in auditing such estimates. How the Critical Audit Matter Was Addressed in the Audit Our audit procedures related to the government rebates, included the following, among others: - We tested the effectiveness of controls over management’s processes to account for the deductions associated with government rebates, including controls over determining the underlying assumptions and key inputs into the Company’s process to calculate government rebate adjustment. - We inspected contractual documents and communications to government agencies and third party advisors associated with the government rebates, and evaluated the consistency of the estimation methodology with the Company’s obligations under such contractual documents and communications. - We tested the mathematical accuracy of the Company’s calculation of the estimates for government rebates. - We evaluated whether the accounting treatment for the anticipated government rebate claims is consistent with the relevant accounting standard, ASC 606 Revenue Recognition. - We performed the following procedures to evaluate the significant assumptions and judgments used by management to estimate the government rebate claims: (i) performing stress tests over certain assumptions and subjective inputs for the government rebates to evaluate the impact on the estimate; (ii) developing a range of independent estimates by using a combination of internal data, third-party data, and pricing experts and comparing this range to the estimate utilized by management; and (iii) performing lookback analyses by comparing amounts invoiced to and paid by the Company to corresponding rebates by the Company and evaluated whether forecast assumption had been appropriately updated where actual rebate claims differed to the amount accrued. /s/ Deloitte LLP Cambridge, United Kingdom February 28, 2024 We have served as the Company’s auditor since 2023. F-3 Table of Contents Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors Immunocore Holdings plc Opinion on the Consolidated Financial Statements We have audited the accompanying Consolidated Balance Sheet of Immunocore Holdings plc and subsidiaries (the Company) as of December 31, 2022, the related Consolidated Statements of Operations and Comprehensive Loss, shareholders’ equity, and cash flows for each of the years in the two year period ended December 31, 2022, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for each of the years in the two year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provides a reasonable basis for our opinion. /s/ KPMG LLP We served as the Company’s auditor from 2009 to 2023 London, United Kingdom February 28, 2024 F-4 Table of Contents Immunocore Holdings Plc Consolidated Balance Sheets (in thousands, except share and per share data) December 31, 2023 December 31, 2022 Assets Current assets Cash and cash equivalents $ 442,626 $ 402,472 Accounts receivable, net 52,093 33,584 Prepaid expenses and other current assets 29,600 37,229 Inventory, net 4,501 692 Total current assets 528,820 473,977 Property and equipment, net 9,215 7,833 Operating lease right of use assets, net 33,520 30,944 Deferred tax assets, net 10,973 5,121 Other non-current assets 14,473 8,887 Total assets $ 597,001 $ 526,762 Liabilities and shareholders’ equity Current liabilities Accounts payable $ 17,798 $ 14,450 Accrued expenses and other current liabilities 119,835 76,747 Deferred revenue, current — 7,756 Operating lease liabilities, current 1,388 1,882 Total current liabilities 139,021 100,835 Accrued expenses, non-current 978 2,215 Deferred revenue, non-current 5,515 5,242 Operating lease liabilities, non-current 34,633 31,760 Interest-bearing loans and borrowings 48,011 47,807 Total liabilities 228,158 187,859 Shareholders’ equity Ordinary shares (voting and non-voting), £ 0.002 par value, most recent authority to allot up to a maximum nominal value of £ 109,335 shares as of December 31, 2023 and 2022, 49,725,649 and 48,088,346 shares issued and outstanding as of December 31, 2023 and 2022, respectively. 134 129 Deferred shares, £ 0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of December 31, 2023 and 2022. 1 1 Additional paid-in capital 1,149,643 1,082,833 Accumulated deficit ( 744,674 ) ( 689,387 ) Accumulated other comprehensive loss ( 36,261 ) ( 54,673 ) Total shareholders’ equity 368,843 338,903 Total liabilities and shareholders’ equity $ 597,001 $ 526,762 The accompanying notes form an integral part of these consolidated financial statements. F-5 Table of Contents Immunocore Holdings Plc Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) Year Ended December 31, 2023 2022 2021 Revenue : Product revenue, net $ 238,735 $ 130,013 $ — Pre-product revenue, net — 10,674 4,078 Total revenue from sale of therapies 238,735 140,687 4,078 Collaboration revenue 10,693 33,674 32,406 Total revenue 249,428 174,361 36,484 Cost and operating expenses: Cost of product revenue ( 1,037 ) ( 1,089 ) — Research and development expense ( 163,545 ) ( 101,921 ) ( 100,248 ) Selling, general and administrative expense ( 144,495 ) ( 123,059 ) ( 110,823 ) Loss from operations ( 59,649 ) ( 51,708 ) ( 174,587 ) Other (expense) income : Interest income 17,986 3,756 65 Interest expense ( 5,154 ) ( 5,409 ) ( 5,573 ) Foreign currency (loss) gain ( 13,176 ) 14,157 289 Other expense, net ( 897 ) ( 1,679 ) ( 73 ) Net loss before income taxes ( 60,890 ) ( 40,883 ) ( 179,879 ) Income tax credit (expense) 5,603 ( 11,660 ) ( 150 ) Net loss $ ( 55,287 ) $ ( 52,543 ) $ ( 180,029 ) Other comprehensive income (loss): Exchange differences on translation of foreign operations 18,412 ( 24,358 ) ( 254 ) Total comprehensive loss ( 36,875 ) ( 76,901 ) ( 180,283 ) Basic and diluted net loss per share $ ( 1.13 ) $ ( 1.15 ) $ ( 4.24 ) Basic and diluted weighted-average number of shares outstanding 48,888,975 45,714,923 42,488,579 The accompanying notes form an integral part of these consolidated financial statements. F-6 Table of Contents Immunocore Holdings Plc Consolidated Statements of Shareholders’ Equity (in thousands, except share data) Ordinary Shares Deferred Shares Additional Paid-in Capital Accumulated deficit Accumulated other comprehensive (loss) income Total Shareholders’ Equity Shares Amount Shares Amount At January 1, 2021 31,782,885 $ 86 5,793,501 $ 1 $ 563,698 $ ( 456,815 ) $ ( 30,061 ) $ 76,909 Net loss — — — — — ( 180,029 ) — ( 180,029 ) Other comprehensive loss — — — — — — ( 254 ) ( 254 ) Issuance of ordinary share, net 12,003,203 32 — — 286,855 — — 286,887 Exercise of share options 76,762 — — — 1,298 — — 1,298 Share-based compensation expense — — — — 48,894 — — 48,894 At December 31, 2021 43,862,850 $ 118 5,793,501 $ 1 $ 900,745 $ ( 636,844 ) $ ( 30,315 ) $ 233,705 Net loss — — — — — ( 52,543 ) — ( 52,543 ) Other comprehensive loss — — — — — — ( 24,358 ) ( 24,358 ) Issuance of ordinary share, net 3,733,333 10 — — 139,505 — — 139,515 Exercise of share options 492,163 1 — — 9,695 — — 9,696 Share-based compensation expense — — — — 32,888 — — 32,888 At December 31, 2022 48,088,346 $ 129 5,793,501 $ 1 $ 1,082,833 $ ( 689,387 ) $ ( 54,673 ) $ 338,903 Net loss — — — — — ( 55,287 ) — ( 55,287 ) Other comprehensive income — — — — — — 18,412 18,412 Exercise of share options 1,637,303 5 — — 34,341 — — 34,346 Share-based compensation expense — — — — 32,469 — — 32,469 At December 31, 2023 49,725,649 $ 134 5,793,501 $ 1 $ 1,149,643 $ ( 744,674 ) $ ( 36,261 ) $ 368,843 The accompanying notes form an integral part of these consolidated financial statements. F-7 Table of Contents Immunocore Holdings Plc Consolidated Statements of Cash Flows (in thousands) Year Ended December 31, 2023 2022 2021 Cash flows from operating activities Net loss $ ( 55,287 ) $ ( 52,543 ) $ ( 180,029 ) Adjustments for: Share-based compensation expense 32,469 32,888 48,894 Depreciation 4,090 5,335 7,591 Unrealized foreign exchange losses (gains) 13,827 ( 14,482 ) 99 Loss on loan extinguishment — 1,686 — Non-cash lease expense 1,647 2,076 2,076 Other 412 ( 4 ) 222 Changes in assets and liabilities: Increase in accounts receivable ( 17,871 ) ( 26,264 ) ( 4,863 ) Decrease (increase) in prepayments and other current assets 8,544 ( 14,694 ) 1,350 Increase in accounts payable 2,625 4,913 1,474 Increase in accrued expenses 39,088 41,757 10,681 Decrease in deferred revenue ( 8,013 ) ( 25,504 ) ( 29,072 ) Decrease in operating lease liabilities ( 2,226 ) ( 1,782 ) ( 2,013 ) (Increase) decrease in other operating assets ( 15,012 ) ( 4,729 ) 361 (Decrease) increase in other operating liabilities ( 1,353 ) 2,138 123 Net cash provided by (used in) operating activities 2,940 ( 49,209 ) ( 143,106 ) Cash flows from investing activities Proceeds from sale of property, plant and equipment — 6 106 Purchase of property, plant and equipment ( 5,425 ) ( 2,203 ) ( 1,386 ) Net cash used in investing activities ( 5,425 ) ( 2,197 ) ( 1,280 ) Cash flows from financing activities Proceeds from issue of ordinary shares, net — 139,515 286,887 Exercise of share options 34,346 9,696 1,298 Loan repayments — ( 50,000 ) — Debt prepayments and extinguishments — ( 2,000 ) — Non-current interest-bearing loan received — 50,000 — Debt issuance payments — ( 1,769 ) — Net cash provided by financing activities 34,346 145,442 288,185 Increase in net cash and cash equivalents 31,861 94,036 143,799 Net foreign exchange difference on cash held 8,293 ( 12,646 ) 625 Cash and cash equivalents at beginning of year 402,472 321,082 176,658 Cash and cash equivalents at end of year $ 442,626 $ 402,472 $ 321,082 Supplemental cash flow information Cash received (paid) for interest, net $ 5,674 $ ( 4,482 ) $ ( 5,708 ) Cash received (paid) for income taxes, net $ ( 977 ) $ ( 765 ) $ 17,044 The accompanying notes form an integral part of these consolidated financial statements. F-8 Table of Contents Immunocore Holdings Plc Consolidated Notes to the Financial Statements 1. Description of Business Immunocore Holdings plc (collectively with its subsidiaries, the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries: Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited with operations based primarily in the U.K. and U.S. The Company is pioneering the development and sale of a novel class of TCR bispecific immunotherapies called ImmTAX – I mmune m obilizing m onoclonal T CRs A gainst X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, the Company is developing a pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. In January and April 2022, the Company received approval from the U.S. Food and Drug Administration, or FDA, and European Commission EC, respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma and has subsequently received approvals in further territories, and the Company continues to launch and seek approvals in additional territories. KIMMTRAK is now approved in over 30 countries and the Company has commercially launched the product in the United States, Germany and France, among other territories. The Company’s American Depositary Shares, or ADS, began trading on the Nasdaq Global Select Market under the ticker symbol “IMCR” on February 5, 2021, following its initial public offering, or IPO. The IPO and concurrent private placement generated net proceeds of $ 286.9 million after underwriting discounts, commissions and directly attributable offering expenses. In July 2022, the Company issued and sold a total of 3,733,333 ADSs and non-voting ordinary shares to certain institutional accredited investors and existing shareholders as a private investment in public entity, or PIPE, pursuant to a securities purchase agreement with such investors, generating net proceeds of $ 139.5 million. Prior to completion of the IPO, Immunocore Holdings Limited was incorporated in England and Wales on January 7, 2021. Effective immediately prior to completion of the IPO, the Company re-organized its share capital whereby all of the outstanding series A preferred shares, series B preferred shares and series C preferred shares were re-designated as ordinary shares of the Company on a one for one basis. Following a subsequent corporate reorganization, Immunocore Holdings Limited became the ultimate parent company for the Company and was re-registered as a public limited company with the name Immunocore Holdings plc, the registrant. The corporate reorganization was accounted for as a business combination under common control and therefore, Immunocore Holdings plc is a continuation of Immunocore Limited and its subsidiaries. The corporate reorganization, further outlined below in Note 9 “Shareholders’ Equity”, was given retrospective effect in the financial statements.. 2. Summary of Significant Accounting Policies Basis of Presentation H istorically, the Company qualified as a foreign private issuer and prepared its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). Effective January 1, 2024, the Company no longer qualifies as a foreign private issuer as defined in Rule 405 of Regulation C under the Securities Act and Rule 3b-4 under the Exchange Act and therefore has become a domestic filer and must file this Form 10-K pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and in accordance with accounting principles generally accepted in the U.S (U.S. GAAP). The Company’s consolidated financial statements were prepared in accordance with U.S. GAAP retrospectively for the fiscal years ended December 31, 2023, 2022, and 2021 and include the financial results of all wholly-owned subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation and the consolidated financial statements are presented in U.S. dollars . Significant Accounting Policies Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as income and expenses in the financial period. The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. F-9 Table of Contents Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the Company’s control. Actual results could differ from those estimates. Estimates are primarily made in relation to revenue recognition, estimation of operating lease incremental borrowing rates, share-based compensation expense, clinical accruals, and deferred tax asset valuation allowances. Segment reporting The Company operates in one operating segment: immunotherapies. We generate our revenue from two streams, collaboration revenue and revenue from the sale of therapies. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (CODM), the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM evaluates financial performance and allocates resources using financial information reported on a company-wide basis . Foreign currencies The reporting currency of the Company is U.S. dollars. The functional currency of the Company’s ultimate parent and each subsidiary is based on the currency of the economic environment in which they operate. Assets and liabilities of each subsidiary with a functional currency that differs to the Company’s ultimate parent are translated into sterling and consolidated. The consolidated balances are then converted into U.S. dollars at period-end exchange rates. Revenues and expenses are translated into sterling, and then reported in U.S. dollars using average exchange rates for each reporting period. Translation adjustments are reflected as accumulated other comprehensive (loss) income. Revenues Pursuant to Accounting Standards Codification, ASC, Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for agreements, the Company performs the following five steps: (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. Product revenue, net Product revenue, net, relates to the sale of KIMMTRAK following marketing approval. The Company recognizes revenue at the point in time that control transfers to a customer, which is typically on delivery. The Company also operates under consignment arrangements where control passes when the Company’s distributors take KIMMTRAK out of consignment inventory. The amount of revenue recognized under its arrangements reflects the consideration to which the Company expects to be entitled, net of estimated deductions for rebates, chargebacks, levies, other customer fees and product returns. Estimated revenue deductions are updated at the end of each reporting period using the latest available data. The Company considers whether any part of amounts expected to be received should be constrained to ensure that it is probable that a significant reversal in the cumulative revenue recognized will not occur. Rebates: Rebates consist of Medicaid and other governmental rebates in the U.S. and other similar programs in Europe. These reserves are recorded as a reduction to revenue in the same period the related revenue is recognized. The Company currently estimates based on internal forecasts of the patient mix, information obtained from claims received and other industry data, and external health coverage statistics. Chargebacks : Chargebacks for discounts represent the Company’s estimated obligations resulting from contractual commitments for specialty distributors to sell KIMMTRAK to qualifying hospitals at a lower price. For such sales, the specialty distributors charge back the difference between the wholesale acquisition cost and this lower price. The Company estimates chargeback deductions by analyzing sell-through data relating to the hospital mix of onward sales made by specialty distributors. F-10 Table of Contents Product returns : The Company estimates the amount of its product sales that may be returned by its customers and records this in the period the related product revenue is recognized. The Company bases product return liabilities on quantitative information provided by the Company’s distributors. The Company’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list prices with standard payment terms typically between one and two months . When the Company has the right to offset chargebacks against accounts receivable and the parties have agreed to settle the payments net, chargebacks are recorded as a reduction in accounts receivable. Other chargebacks, rebates and deductions are recognized in Accrued expenses and other current liabilities and Accrued expenses, non-current in the Consolidated Balance Sheets. In certain countries, the Company’s customers are hospitals and healthcare providers, where KIMMTRAK is sold through an agent acting on the Company’s behalf. Product revenue also includes amounts for partnered revenue, which is recognised on delivery and transfer of title to Medison Pharma Ltd, or Medison, the Company’s exclusive distributor in certain countries outside the U.S. Pre-product revenue, net Pre-product revenue, net, relates to the sale of tebentafusp under a compassionate use and an early access program in France up to September 2022. These programs provided patients with access to tebentafusp before KIMMTRAK became available as a marketed product in France. Pre-product revenue is recognized on delivery of tebentafusp to healthcare providers, which is the point in time when control is transferred. Such revenue is recognized net and represents the prices set by the Company that are expected to be retained after estimated deductions and to the extent that it is probable that a significant reversal of revenue will not occur. These variable estimated deductions include both an estimate of government rebates and levies payable, and an estimate of returns in the case of expiry, damage or other instances. The total rebate payable by the Company is dependent on the outcome of price negotiations with the French government, and the Company makes an estimate of these amounts payable each reporting period based on available pricing information and the applicable regulations. The estimates for rebates and returns deducted from pre-product revenue are recorded in the period the related pre-product revenue is recognized and are classified under Accrued expenses and other current liabilities and Accrued expenses, non-current in the Consolidated Balance Sheets. Costs of pre-product revenue are expensed when incurred and include costs associated with previous manufacturing of tebentafusp and other third-party selling expenses. Previous manufacturing costs were recognized in research and development (R&D) expenses at the time, and third-party selling expenses are recognized within Selling and administrative expenses. Collaboration revenue We analyze our collaboration agreements to assess whether they are within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC 808, we assess whether aspects of the arrangement between us and the collaboration partner are within the scope of other accounting literature. If we conclude that some or all aspects of the arrangement represent a transaction with a customer, we account for those aspects of the arrangement within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). If we conclude that some or all aspects of the arrangement are within the scope of ASC 808 and do not represent a transaction with a customer, we recognize our share of the allocation of the shared costs incurred with respect to the jointly conducted activities as a component of the related expense in the period incurred. Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. If we conclude a counterparty to a transaction is not a customer or otherwise not within the scope of ASC 606 or ASC 808, we consider the guidance in other accounting literature as applicable or by analogy to account for such transaction. We determine the units of account within the Collaboration Agreement utilizing the guidance in ASC 606 to determine which promised goods or services are distinct. In order for a promised good or service to be considered “distinct” under ASC 606, the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct), and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). The Company has concluded that it has customer relationships with its collaborators and therefore, the Company follows the guidance in ASC Topic 606, Revenue from Contracts with Customers. Under ASC 606, the Company determines whether milestones or other variable consideration should be included in the transaction price, whether performance obligations are satisfied at a point in time or over time, and the appropriate method of measuring progress for the purposes of revenue recognition for performance obligations satisfied over time. Under each of its collaboration agreements, the Company granted rights to technology with respect to the development of specified targets and the commercialization of future product candidates for such targets defined in the respective agreements. In addition, the Company was required to perform R&D services, participate on a joint steering committee and the agreements also provided parties with the option to obtain exclusive rights to the associated intellectual property license. The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). The Company determined that these promises represented specialized, combined performance obligations, which were satisfied over time and deemed fully satisfied on completion of the development services for the specified period and when the collaborator is contractually entitled to benefit from the exclusive rights to the associated intellectual property license either through the collaborator exercising an option to do so or at the Company’s election. Further, the Company determined that their collaborators cannot benefit from the associated intellectual property licenses separately from the R&D activities and participation on the joint steering committee because these services are specialized and rely on the Company’s expertise such that these activities are highly interrelated and therefore not distinct. F-11 Table of Contents The Company estimates the transaction price based on the amount it expects to be entitled to for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential payment and the likelihood that the underlying constraint will be released. Under certain of the Company’s collaboration agreements, development milestones and reimbursements of research and development costs incurred either in excess of a defined amount, or in accordance with a cost sharing agreement are considered variable consideration.Variable consideration may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Revenue is recognized as the programs progress through stages of R&D using an estimate of percentage completion which takes into consideration the estimated timelines required to satisfy the performance obligation and the time taken since program nomination. The determination of the percentage of completion requires the estimation of when the performance obligation will be completed, based on the latest project plan and discussions with project teams and will consider progress achieved to date, historical experience on similar programs and other internal factors as may be available. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate is recognized as an adjustment to revenue in the period in which the change in estimate occurs. The Company’s collaboration revenue arrangements have standard payment terms and do not contain a significant financing component. Deferred revenue The Company’s deferred revenue as of December 31, 2023 and 2022 is related to the collaboration agreements further outlined below in Note 3. “Revenue.” Following termination of its collaborations with GSK and Eli Lilly, and the agreement with Genentech in 2023 to close the IMC-C103C trial, the Company currently expects no further revenue or deferred revenue from its collaborations. The Company has a revenue partnership with Medison relating to the supply and distribution of KIMMTRAK and is classified within Product revenue in accordance with ASC 606 . The Company’s deferred product revenue relates to a non-refundable upfront receipt from Medison under an amended agreement entered into in November 2022. The Company determined that this receipt relates to the distribution of KIMMTRAK in South America and assessed the Company has a single performance obligation to provide KIMMTRAK to Medison for onward sale under exclusive distribution license. The deferred revenue is expected to be released with the sale of products following regulatory approval in the territory. Accounts receivable Accounts receivable includes amounts invoiced or contractually accrued where only the passage of time is required before payment is received under the Company’s revenue arrangements. Such receivables principally relate to KIMMTRAK sales. An allowance for lifetime expected credit losses on accounts receivable is measured using historical credit loss experience, conditions at the end of each reporting period, and reasonable and supportable forecasts that affect collectability. Expected credit losses at the end of Decem ber 31, 2023 and 2022 were immaterial. Inventory Inventory includes KIMMTRAK manufactured for commercial sale, items in the process of being manufactured for sale, and materials to be used in the manufacturing process for such sale. The principal costs in manufacturing the Company’s inventory are raw materials, external manufacturing costs, and other costs incurred in bringing inventory to its location and condition prior to sale. Inventory is recorded at weighted average cost and presented as an asset in the Consolidated Balance Sheets at the lower of cost and net realizable value. The Company assesses whether an expense should be recognized as a result of writing down inventory values at each reporting period for excess inventory at risk of expiry. Such expenses are recorded as a component of Cost of product revenue in the Consolidated Statements of Operations and Comprehensive Loss in the period during which they are first identified. The Company records inventory costs for potential products within R&D expenses until regulatory approval is considered probable, after which the Company capitalizes subsequent costs related to the production of inventories. Certain inventory can be used for clinical purposes or for commercial products, and the Company records such items within R&D expenses at the point that the vials are assigned for clinical use. Cost of product revenue Cost of product revenue represents production costs including raw materials, external manufacturing costs, and other costs incurred in bringing inventory to its location and condition prior to sale. Overheads and internal costs of product revenue are minimal under our manufacturing arrangements. Cost of product revenue may also include write-off costs and provisions related to excess or obsolete inventory. F-12 Table of Contents Research and development (R&D) expense R&D costs are expensed as incurred and include (i) employee-related expenses, including salaries, benefits, travel and share-based compensation expense for employees engaged in R&D functions; (ii) external R&D expenses incurred under arrangements with third parties, such as contract research organization (CRO) agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials, including the cost of consultants and contract manufacturing organization (CMOs); (iv) costs associated with preclinical and clinical activities and regulatory operations; (v) costs incurred in development of intellectual property, (vi) and depreciation and R&D facilities costs. The Company estimates accrued expenses at each balance sheet date based on facts and circumstances known at that time. These estimates are based on reviews of open contracts, reports provided by the CROs and internal reviews to estimate the level of service performed and the associated cost incurred for those services when the Company has not yet been invoiced or otherwise notified of the actual cost. In accruing clinical trial expenses, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate made, the expense is adjusted accordingly. Where payments made to CROs or other parties exceed the level of services provided, a prepayment is recorded in the Consolidated Balance Sheets. Share-based compensation The Company operates equity-settled, share-based compensation plans whereby employees and directors are granted options to purchase shares in the Company. The fair value of grants is expensed over the vesting period, which is the period in which the services are received. The majority of the Company’s awards have graded vesting schedules, and the expense for these options is recognized over the requisite service period for each separately vesting portion as if the grant of options, in substance, represented multiple awards. The grant date fair value of options is calculated using the Black Scholes valuation model. Estimation of fair value requires judgement, including assumptions about the expected term of share-based options and expected volatility, which are used to determine the fair value of the Company’s options granted. The expected term is based on the Company’s assessment of the period within which participants are expected to exercise options, which requires consideration of employee groups, expected employee service, and other internal factors, and the degree to which these are expected to shorten the term of options in comparison to contractual expiry dates. Estimated expected volatility is based on a combination of the Company’s share price volatility since its IPO and the historical data of a group of comparator companies. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the awards is indicative of future trends, which may not necessarily be the actual outcome. The Company does not assume dividend payments for the purposes of estimating fair value and uses a zero-coupon U.S. Treasury yield curve applicable for the period of the expected term to form an estimate of the risk-free rate. Forfeitures expected to occur are estimated considering both market and company-specific data and the available internal information at the end of each reporting period. Income tax Income tax includes components of current and deferred tax and is recognized in the Consolidated Statements of Operations and Comprehensive Loss. Current tax is the expected tax payable or receivable on the taxable income or loss for the current or prior periods using tax rates enacted at the balance sheet date. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amount and the tax bases of assets and liabilities at the applicable tax rates and for operating loss and tax credit carryforwards. A valuation allowance reduces deferred tax assets in the Consolidated Balance Sheets to reflect the amount that is more likely than not to be realized. The Company evaluates the realizability of its deferred tax assets at each reporting period and adjusts the valuation allowance accordingly, considering income forecasts, availability of carrybacks, taxable temporary differences and other factors affecting the realization of deferred tax assets. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2023 and 2022, the Company has no t recorded any provision for uncertain tax positions. F-13 Table of Contents Changes in the Company’s estimate of income tax positions relating to the more-likely-than-not threshold are recognized in the first subsequent period following the threshold being met or ceasing to be met. R&D expenditure credits The Company receives R&D expenditure credits to compensate for its research activities, which are recognized when it is more likely than not the Company will meet the terms for receiving and realizing the benefit of the credits. Recognition is on a systematic basis over the periods in which the Company recognizes costs for which the credits are intended to compensate (i.e. qualified expenses). The Company benefits in the United Kingdom from His Majesty’s Revenue & Customs (“HMRC”) R&D expenditure (“RDEC”), which provides relief against U.K. corporation tax. Based on criteria established by HMRC a portion of the Company’s expenditures incurred on R&D activities are eligible for RDEC relief. The Company recognizes the benefit as a reduction of the related expenses included in R&D costs on the Consolidated Statements of Operations and Comprehensive Loss. Historically, the Company satisfied the definition of a Small and Medium-sized Enterprise (“SME”) and was able to surrender some of its U.K. tax losses for a cash rebate of up to 33.35 % of expenditures related to eligible R&D projects. The Company exceeded the size limit thresholds and no longer qualifies for tax relief under the U.K. SME R&D regime in 2023. Leases The Company assesses whether contracts represent or contain leases at inception by determining whether the Company has the right to use, or control the use of, an identified asset from which it can obtain substantially all the economic benefits for a defined period. The Company leases its corporate headquarters in the United Kingdom, where its facilities contain R&D, laboratory and office space of approximately 123,000 square feet. In addition, the Company leases approximately 20,000 square feet of office space in the United States, and small offices in Ireland and Switzerland. The leases in the United Kingdom expire between 2037 and 2043. Estimates of the term consider non-cancellable periods and include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date. Right-of-use assets are initially measured at cost, representing the initial amount of the lease liability and any initial direct costs incurred, with a reduction for any lease incentives received. Lease liabilities are initially measured at the present value of the lease payments. Since the rate implicit in leases is not readily determinable, the Company uses available information to determine its incremental borrowing rates, which represent the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments in a similar economic environment. Fixed lease components include rental payments at inception and termination costs for leases not reasonably certain of extension. Such components are accounted for as part of the right-of-use assets and lease liabilities and recognized on a straight-line basis over the lease term. Variable lease components include subsequent indexation-related rental increases. If such variable components do not coincide with a remeasurement of the lease term, the additional costs are recorded as a variable component of the lease expense in the Consolidated Statements of Operations and Comprehensive Loss as incurred. Non-lease components such as maintenance costs and service charges are separated from lease components and recognized separately in the Consolidated Statements of Operations and Comprehensive Loss. Operating lease costs are allocated to R&D and Selling, general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. The related lease cash flows are categorized under Net cash used in operating activities in the Consolidated Statements of Cash Flows. The Company elects not to recognize right-of-use assets and lease liabilities for short-term leases with a term of 12 months or less containing no repurchase options reasonably certain of exercise, and the expense for these short-term leases is immaterial. The Company does not have financing leases. Property and equipment Property and equipment are stated at cost net of accumulated depreciation and impairment losses. The Company expenses repairs and maintenance related to property and equipment in the Consolidated Statements of Operations and Comprehensive Loss when the costs are incurred. Depreciation is charged to the Consolidated Statements of Operations and Comprehensive Loss on a straight-line basis over the estimated useful lives of assets as follows: • Leasehold improvements - shorter of expected lease term and useful life of the asset • Laboratory equipment - 3 to 5 years • Office equipment and other assets - 3 to 5 years F-14 Table of Contents Impairment of long-lived assets The Company periodically assesses whether circumstances indicate that the estimated remaining useful life of its long-lived assets should be changed or that the carrying value of such assets may be impaired. The Company did no t identify any such circumstances or recognize any impairment charges for the years ended December 31, 2023, 2022 and 2021. Cash and cash equivalents Cash and cash equivalents comprise cash balances and short-term money market funds with an original maturity of less than three months. Money market funds are presented at fair value in the Consolidated Balance Sheets. Concentrations of credit risk and off-balance sheet risk Financial instruments that potentially subject the Company to concentrations of credit risk are accounts receivable, cash equivalents and deposits held with banks and financial institutions. Cash, cash equivalents and deposits are maintained with high-quality financial institutions in Europe and the United States. The Company has not experienced any credit losses with such institutions and has incurred an immaterial amount of losses in relation to its accounts receivable from customers The Company has no financial instruments with off-balance sheet risk of loss. As of December 31, 2023 and 2022, the amounts of expected credit losses recognized in the Consolidated Balance Sheets were not materia l . Interest-bearing loans and borrowings The Company offsets issuance costs against the initial value of the debt on the Company’s Consolidated Balance Sheets and amortizes the costs over the loan term using the effective interest method. Such costs are recognized under Interest expense in the Consolidated Statements of Operations and Comprehensive Loss and under Accrued expenses on the Consolidated Balance Sheets. Fair value measurements Where financial and non-financial assets and liabilities are measured at fair value, the Company uses appropriate valuation techniques for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: • Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices). • Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs), and that are significant to the fair value of the assets or liabilities. As of December 31, 2023 and 2022, the Company held $ 331.0 million and $ 191.9 million, respectively, of money market funds required to be measured at fair value on a recurring basis. The fair value of these cash equivalents is based on quoted prices from active markets (Level 1 inputs). The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the changes have occurred. There were no transfers between levels of fair value hierarchy in the years ended December 31, 2023 and 2022. Other financial instruments, although not recorded at fair value on a recurring basis, include cash, accounts receivable, accounts payable and debt obligations. The fair value of borrowings under the Pharmakon Loan Agreement (disclosed in Note 7. “Non-current interest-bearing loans and borrowings”) were based on Level 2 inputs, which include observable inputs estimated using discounted cash flows and market-based expectations for interest rates, credit risk, and the contractual terms of debt instruments. After initial recognition, borrowings are measured at amortized cost using the effective interest method. F-15 Table of Contents Net loss per share Basic and diluted net loss per share is calculated by dividing the net loss for the period by the weighted average number of ordinary shares outstanding during the period. The dilutive effect of potential ordinary shares through share options are considered to be anti-dilutive as they would decrease the net loss per share and are therefore excluded from the calculation of diluted net loss per share. Recently issued and recently adopted accounting pronouncements I n November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures . This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and clarified that single reportable segment entities must apply Topic 280 in its entirety. This guidance is effective for the Company for the year beginning January 1, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statement. We are currently assessing the impact of this guidance on our disclosures . I n December 2023, the FASB issued ASU 2023-09 , Improvements to Income Tax Disclosures . This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. We are currently assessing the impact of this guidance on our disclosures . 3. Revenue Revenue from sale of therapies (in thousands) 2023 2022 2021 Product revenue $ 238,735 $ 130,013 $ — Pre-product revenue — 10,674 4,078 Total revenue from sale of therapies 238,735 140,687 4,078 Collaboration revenue GSK — — 8,385 Eli Lilly — 9,205 — Genentech 10,693 24,469 24,021 Total collaboration revenue 10,693 33,674 32,406 Total revenue $ 249,428 $ 174,361 $ 36,484 Product revenue, net During the year ended December 31, 2023, the Company recognized $ 238.7 million (2022: $ 130 million) of net product revenue relating to the sale of KIMMTRAK primarily in the United States and Europe after estimated deductions for rebates, chargebacks, other customer fees and returns, which are recognized in Accrued expenses and other current liabilities as set out in the Company’s accounting policies. Pre-product revenue, net There was no pre-product revenue during the year ended December 31, 2023, following the transition to the commercial sale of KIMMTRAK in France in the second half of 2022. During the year ended December 31, 2022 and 2021, the Company recognized $ 10.7 million and $ 4.1 million of net pre-product revenue, respectively, relating to the sale of tebentafusp under compassionate use and early access programs in France after estimated deductions for rebates and returns, which are recognized in Accrued expenses and other current liabilities as set out in the Company’s accounting policies. The Company recognized revenues from four customers accounting for 29 %, 26 %, 17 % and 16 % of the Company’s total revenue from the sale of therapies for the year ended December 31, 2023, five customers accounting for 26 %, 25 %, 17 %, 17 % and 12 % of the Company’s total revenue from the sale of therapies for the year ended December 31, 2022, and one customer accounted for all revenue from the sale of therapies for the year ended December 31, 2021. F-16 Table of Contents Net product revenue from the sale of KIMMTRAK, and net pre-product revenue are presented by country / region based on the location of the end customer below (in thousands). 2023 2022 2021 United States $ 169,791 $ 96,893 $ — Europe 67,628 42,745 4,078 International 1,316 1,049 — Total revenue from sale of therapies $ 238,735 $ 140,687 $ 4,078 Net product revenue for the year ended December 31, 2023 includes $ 3.6 million (2022: $ 1.9 million, 2021: none ) of partnered revenue under our agreement with Medison, split between our European and international markets. Of the Company’s collaboration customers, Eli Lilly and Genentech are based in the United States. GSK is based in the United Kingdom. The revenue for Genentech represented more than 10 % of the Company’s total revenue during 2022. During 2021, the revenue for GSK and Genentech represented more than 10 % of the Company’s total revenue. Accounts receivable from contracts with customers Accounts receivable, net as of December 31, 2023 and 2022 were as follows (in thousands): 2023 2022 Beginning balance $ 33,584 $ 7,334 Additions 307,255 206,442 Payments received ( 288,211 ) ( 180,192 ) Provision ( 535 ) — Ending balance $ 52,093 $ 33,584 As of December 31, 2023, four customers individually accounted for approximately 31 %, 26 %, 19 % and 16 % of accounts receivable associated with the Company’s revenue from the sale of therapies, as compared to 27 %, 25 %, 23 % and 20 % as of December 31,2022. As of December 31, 2023 and 2022, the amount of expected credit losses on accounts receivable was not material. Accruals for rebates and chargebacks Current and non-current accruals for rebates, chargebacks and returns as of December 31, 2023 and 2022 were as follows (in thousands): Rebates Chargebacks Returns Total As of January 1, 2022 $ 3,391 $ — $ — $ 3,391 Provisions related to sales in the period 24,141 16,597 969 41,707 Credits and payments made ( 1,115 ) ( 12,944 ) ( 121 ) ( 14,180 ) As of December 31, 2022 $ 26,417 $ 3,653 $ 848 $ 30,918 Provisions related to sales in the period 59,160 25,467 1,937 86,564 Adjustments related to prior period sales ( 1,861 ) ( 734 ) ( 237 ) ( 2,832 ) Credits and payments made ( 19,759 ) ( 26,355 ) ( 1,810 ) ( 47,924 ) As of December 31, 2023 $ 63,957 $ 2,031 $ 738 $ 66,726 The adjustments related to prior period sales in the year ended December 31, 2023 was due to changes in estimates primarily related to the pricing agreement signed for Germany in August 2023. Deferred revenue For the year ended December 31, 2023, a total of $ 7.8 million of revenue recognized was included in Deferred revenue as of January 1, 2023 (2022: $ 33.0 million ; 2021: $ 29.1 million). Deferred revenue in the Consolidated Balance Sheets is primarily in respect of the upfront fee and development milestone consideration received from the various collaboration agreements in advance of services performed by the Company. Non-current deferred revenue in the Consolidated Balance Sheet as of December 31, 2023, relates to a revised distribution agreement with Medison entered into in November 2022. Under the revised agreement, the Company received a non-refundable payment of $ 5.0 million in exchange for granting Medison exclusive distribution rights in South America. The Company has determined that the deferred revenue relates to the Company’s single, combin ed performance obligation to supply KIMMTRAK to Medison and to grant Medison the exclusive right to distribute KIMMTRAK in South America. The Company expects to recognize this revenue with the sale of products following regulatory approval in the territory. The Company estimates that Product revenue recognition of this non-current deferred revenue will commence after one year or later. Revenue recognized relating to performance obligations satisfied in previous years was zero for all years presented. F-17 Table of Contents Genentech Collaboration Under the Genentech agreement signed in November 2018, the Company received aggregate non-refundable payments totaling $ 100 million consisting of an initial upfront payment of $ 50 million and $ 50 million paid upon an investigational new drug filing for the first clinical trial of the product candidate compound, in exchange for granting Genentech rights to co- develop/co-promote the Company ’s IMC-C103C program and the co-exclusive worldwide license to the Company ’s intellectual property rights in MAGE A4 soluble TCR bispecific therapeutic candidate compounds. The Company was responsible for development of the IMC-C103C program over the period of time to estimated completion of the Phase 1 clinical trial, with costs being shared equally with Genentech. In February 2023, as the Company elected to withdraw from co-funding with Genentech the MAGE-A4 HLA-A02 program, IMC-C103C, Genentech acquired an exclusive worldwide license to the MAGE-A4 HLA-A02 soluble TCR bispecific therapeutic candidate compounds and shall be fully responsible for all further development and commercialization of such candidate compounds, at its expense. The transaction price was recorded as deferred revenue on receipt in November 2018 and allocated to a single combined performance obligation covering the granting of the co-exclusive worldwide license, the provision of development services and participation on a joint steering committee. This deferred revenue is recognized as the Company satisfies the combined performance obligation over the estimated period of time to when the Company has completed substantially all of its responsibilities associated with its withdrawal from the co-funding and the Phase I clinical trial. R&D costs reimbursed under the 2018 Genentech Agreement are considered variable consideration and not recognized in the transaction price until it is probable that the recognition of such revenue will not be reversed. During the year ended December 31, 2023, the Company recognized $ 10.7 million of revenue relating to the 2018 Genentech Agreement (2022: $ 24.5 million; 2021: $ 24.0 million). The revenue recognized represents both deductions from deferred revenue and R&D costs reimbursed, predominantly for clinical trial costs. Such reimbursements arise in or der to ensure that R&D costs are shared equally in accordance with the 2018 Genentech agreement. The revenue recognized in 2023 represents the remaining transaction price relating to the unsatisfied performance obligation as of December 31, 2022, and the unsatisfied performance obligation was expected to be fully recognized within one year. As of December 31, 2023, the Company determined its performance obligation under its collaboration with Genentech was complete. The Company determined achieving commercialization milestones and royalties to be unlikely and were excluded from the transaction price as of December 31, 2023, 2022 and 2021, therefore any future milestones will be recorded when they become probable of being achieved. Lilly Collaboration In July 2014, the Company entered into a development and license agreement with Eli Lilly, or the Lilly Agreement, pursuant to which the Company and Eli Lilly agreed to collaborate in the development, manufacture and commercialization of soluble TCR bispecific therapeutic compounds. Under the Lilly Agreement, Eli Lilly paid an initial non-refundable upfront fee payment of $ 45 million in exchange for options to three targets. Following termination of the agreement, Eli Lilly no longer has any rights to the targets or the ability to nominate any further targets under the initial agreement. The transaction price, equal to the $ 45.0 million upfront payment was recorded as deferred revenue on receipt and was allocated to each target based on the relative standalone selling price. Each target had a single combined performance obligation covering the provision of R&D services and participation on a joint steering committee. This deferred revenue was recognized as the Company satisfied the combined performance obligations over the estimated period of time to when Eli Lilly could exercise the option to obtain exclusive co-development/co-promotion rights to the target and the Company could opt-out of the co-development of the target. The Company released the remaining deferred revenue attributed to the third target under the Lilly Collaboration after the parties agreed to terminate the agreement in March 2022. No further revenue under the collaboration has been recognized. During the year ended December 31, 2023, the Company recognized no re venue relating to the Lilly Agreemen t ( 2022: $ 9.2 million; 2021: no revenue). F-18 Table of Contents GSK Collaboration In June 2013, the Company entered into a collaboration and license agreement with GSK pursuant to which the Company and GSK agreed to collaborate in the development of soluble TCR bispecific therapeutic compounds (the “GSK Agreement”). Under the GSK Agreement, the Company granted GSK the right to nominate up to four exclusive targets . The first target, GSK01/NY-ESO, was nominated at the time of execution of the GSK Agreement. A second target was nominated in July 2017. GSK subsequently had no further ability to nominate additional targets under the terms of the agreement. Following a review of the targets in the year ended December 31, 2021, the parties elected not to proceed further with the second target and the GSK Agreement was terminated in January 2022. The transaction price at the time the agreement was entered was equal to the total payments received of $ 27.8 million. The total payments were recorded as deferred revenue on receipt and were allocated to each target based on the relative standalone selling price. Each target had a single combined performance obligation covering the provision of R&D services and participation on a joint steering committee. This deferred revenue was recognized as the Company satisfied the combined performance obligation over the estimated period that GSK could exercise the option to obtain an exclusive worldwide license for the therapeutic candidate compounds. R&D costs reimbursed under the GSK Agreement were considered variable consideration and assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it was probable that the recognition of such revenue would not be reversed. During the year ended December 31, 2023, the Company recognized no revenue relating to the GSK Agreement (2022: no revenue; 2021: $ 8.4 million) following termination of the agreement in 2021. Other information Substantially all of the Company’s assets are held in the United Kingdom. The total of non-current assets other than financial instruments and deferred tax assets located in the United Kingdom as of December 31, 2023 is $ 55.4 million (2022: $ 43.7 million). The total located in the United States is $ 1.8 million (2022: $ 2.7 million). 4. Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the following (in thousands): 2023 2022 Prepayments $ 10,547 $ 10,109 R&D tax credit 5,798 14,250 VAT receivable 3,544 9,249 Other current assets 9,711 3,621 $ 29,600 $ 37,229 Included within other current assets are amounts paid in advance to clinical research organizations that are expected to be received through services rendered or repaid within 12 months. 5. Property and equipment, net Property and equipment, net, consists of the following (in thousands): 2023 2022 Leasehold property improvements $ 20,020 $ 19,095 Laboratory equipment 39,534 32,265 Office equipment and other assets 1,922 1,710 Construction in progress 46 431 Total property and equipment, gross 61,522 53,501 Less: Accumulated Depreciation ( 52,307 ) ( 45,668 ) Total property and equipment, net $ 9,215 $ 7,833 Depreciation expense for the year ended December 2023, 2022 and 2021 was $ 4.1 million, $ 5.3 million and $ 7.6 million, respectively. 6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consists of the following (in thousands): 2023 2022 Rebates, chargebacks, other customer fees and returns $ 66,726 $ 29,128 Clinical accruals 22,459 25,371 Contract manufacturing 4,356 2,535 Commercial services 6,900 5,761 Employee related expenses 11,598 9,150 Other taxation and social security 1,807 1,122 Other accruals 5,989 3,680 $ 119,835 $ 76,747 See Note 3 “Revenue” for a detailed breakdown of Rebates, chargebacks, other customer fees and returns. Clinical accruals primarily represent unbilled work undertaken by Contract Research Organizations (CRO’s) as part of our clinical programs. F-19 Table of Contents 7. Non-current interest-bearing loans and borrowings 2023 2022 I nterest-bearing loans and borrowings (in thousands) $ 48,011 $ 47,807 $ 48,011 $ 47,807 On November 8, 2022, the Company entered into the Pharmakon Loan Agreement, providing for term loans to the Company in an aggregate principal amount of up to $ 100 million to be funded in two tranches. The first tranche of $ 50 million bears interest at a fixed rate of 9.75 %, which is payable quarterly in arrears, with payments commencing in 2023. The Company used the proceeds after drawing down the first tranche of $ 50 million under the Pharmakon Loan Agreement to repay and close the Company’s previous loan with Oxford Finance. Thereafter no further amounts may be borrowed pursuant to the loan agreement with Oxford Finance, and no further amounts are due. The total payments made for the exit fee on the loan with Oxford Finance and attributable fees to the agreement with Pharmakon were $ 3.8 million. The Company is also required to pay a further fee of $ 1.25 million at the latest by June 2024, regardless of whether it elects to draw down on the second $ 50 m tranche under the Pharmakon Loan Agreement. The second tranche, consisting of one or two term loan(s) of up to $ 50 million is available until June 30, 2024, and may be advanced at the Company’s election. The Pharmakon loan agreement has a maturity of November 8, 2028 . As of December 31, 2023 and 2022, debt fees and issuance costs incurred with loans under the Pharmakon agreement were zero and $ 2.2 million, respectively, and are being amortized as interest expense on an effective interest rate method over the remaining term of the loan. As of December 31, 2023 and 2022, the fair value of the loan was $ 46.1 million and $ 47.6 million, respectively. These values were determined based on prevailing interest rates as of the balance sheet dates and are classified as Level 2 within the fair value hierarchy. The Company has pledged its total assets of $ 597.0 million, presented in the Consolidated Balance Sheet as of December 31, 2023 as collateral for the $ 50 million loan drawn down under the Pharmakon Loan Agreement. In the event the Company was unable to repay the loan, these pledged assets would instead be used to repay the outstanding amount of loan and interest. The Company’s borrowings under the Pharmakon Loan Agreement, contain customary representations and warranties and customary affirmative and negative covenants, including limitations on the Company’s ability to dispose of assets, enter into merger, consolidation or acquisition transactions, and incur additional debt. The Company monitors these covenants and is in compliance. The Company originally entered into its loan and security agreement with Oxford Finance in November 2020 for the provision of up to $ 100 million debt financing to be provided under three tranches, of which the first tranche of $ 50 million was received on signing the agreement. Borrowings under the Oxford Finance Agreement bore interest at an annual rate equal to LIBOR plus 8.85 %, with a minimum rate of 9.01 % and a maximum rate of 12.01 % and were repayable in monthly interest-only payments. The Company recorded a loss on extinguishment of the debt of $ 1.7 million within Other (expense) income, net in the Company’s Consolidated Statements of Operations and Comprehensive Loss for the year ended December 31, 2022, representing the difference between the reacquisition price and the net carrying amount of the outstanding loans extinguished. As of December 31, 2023, future principal payments due are as follows (in thousands): 2024 $ - 2025 - 2026 6,250 2027 25,000 2028 18,750 Total principal payments $ 50,000 F-20 Table of Contents 8. Leases The Company’s costs as a lessee for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands): 2023 2022 2021 Operating lease cost $ 4,219 $ 3,750 $ 3,912 Variable lease cost 253 129 29 Total lease costs $ 4,472 $ 3,879 $ 3,941 Supplemental cash flow information related to leases for the years ended December 31, 2023, 2022 and 2021 were as follows (in thousands): 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Total cash outflow for leases $ 4,633 $ 3,954 $ 4,374 Supplemental non-cash information: Right-of-use assets obtained in exchange for new lease obligations $ 2,783 $ 3,021 $ 44 The weighted average remaining lease term and weighted average discount rate of operating leases at December 31, 2023 and 2022 were as follows: 2023 2022 Weighted average lease term remaining 14.1 years 14.8 years Weighted average discount rate 7.2 % 7.2 % The maturities of operating lease liabilities as of December 31, 2023 are as follows (in thousands): 2023 2024 $ 3,858 2025 3,874 2026 3,840 2027 3,661 2028 3,844 Thereafter 42,211 Total lease payments 61,288 Less imputed interest ( 25,267 ) Present value of operating lease liabilities $ 36,021 In October 2023, the Company entered into a lease agreement for approximately 19,000 square feet of office space in the United States. The lease is expected to commence in July 2024 and expire in July 2035, although it may be terminated earlier at the Company’s election. The Company will recognize an initial right-of-use asset and associated lease liability of $ 5.5 million and $ 5.5 million, respectively, at lease inception. 9. Shareholders’ Equity The Company had 49,725,649 and 48,088,346 ordinary shares issued and outstanding as of December 31, 2023 and 2022, respectively, with a par value of £ 0.002 per share. In addition there are 5,793,501 deferred shares as of December 31, 2023 and 2022 which are £ 0.0001 per share. The Company has reserved 4,172,055 authorized shares for future issuance under the Equity Incentive Plan (“EIP”). See Note 10 “Share-based compensation” for a description of the EIP. Included within ordinary shares at December 31, 2023 and 2022 are 1,714,650 and 2,164,960 of ordinary shares with no voting rights, respectively. All ordinary shares are entitled to receive dividends and assets available for distribution. Deferred shares have no voting rights, are not entitled to dividends and are only entitled to receive amounts paid up on the deferred shares out of assets available for distribution after all payments have been made to holders of ordinary shares for amounts paid up or payable on such shares. No dividends were paid or declared in the years ended December 31, 2023, 2022 and 2021. F-21 Table of Contents On February 3, 2021, the Company passed an ordinary resolution which authorizes the Directors, or any duly authorized committee of the directors, to allot shares in the Company or grant rights to subscribe for or convert any security into shares in the Company up to an aggregate nominal value of £ 150,000 for a period expiring five years (up to February 3, 2026). This amount may be renewed, varied or revoked by the Company in a general meeting. Private investment in public equity (“PIPE”) In July 2022, the Company issued and sold 2,000,000 ADSs, with each ADS representing one ordinary share of nominal value £ 0.002 and 1,733,333 non-voting ordinary shares of nominal value £ 0.002 each, to certain institutional accredited investors and existing shareholders (the “Investors”) at a purchase price of $ 37.50 per ADS / non-voting ordinary share pursuant to a securities purchase agreement with such Investors dated July 15, 2022, generating net proceeds of $ 139.5 million. IPO and Impact of Corporate Reorganization On January 7, 2021, Immunocore Holdings Limited was incorporated as a private limited company under the laws of England and Wales with nominal assets and liabilities for the purpose of becoming the holding company of Immunocore Limited. On January 22, 2021, each holder of series A preferred shares, series B preferred shares, series C preferred shares, Growth Shares and ordinary shares in Immunocore Limited, sold and transferred their shares to Immunocore Holdings Limited in exchange for 100 shares of the same class at par value of 0.01 pence in Immunocore Holdings Limited. Following this share exchange, Immunocore Limited became a wholly owned subsidiary of Immunocore Holdings Limited. All Immunocore Limited share options granted to directors and employees under share option plans that were in existence immediately prior to the reorganization were exchanged for share options in Immunocore Holdings Limited on a one-for- 100 basis. Following the share exchange, Immunocore Limited undertook a reorganization of its share capital to re-designate its series A preferred shares, series B preferred shares, series C preferred shares and Growth Shares into a single class of ordinary shares and subsequently undertook a share capital reduction, cancelling all amounts standing to the credit of its share premium account and cancelling 6,414,412 ordinary shares. On February 1, 2021, Immunocore Holdings Limited was re-registered as a public limited company (“plc”) with the name Immunocore Holdings plc. The Company’s consolidated assets and liabilities immediately following the reorganization were the same as Immunocore Limited immediately before the reorganization. Effective immediately prior to completion of the IPO, the Company re-organized its share capital whereby all of the outstanding series A preferred shares, series B preferred shares and series C preferred shares were re-designated as ordinary shares of the Company on a one for one basis. A total of 16,632,540 of the ordinary shares, following the re-designation of the series C preferred shares, were converted to a separate class of non-voting ordinary shares. A total of 6,250,000 Growth Shares were re-designated of which 4,324,000 of the Growth Shares were re-designated as deferred shares of the Company. The remaining 1,926,000 Growth Shares were re-designated in the ratio of one ordinary share, issued for non-cash consideration and three deferred shares. Immediately following these re-designations referred to above every 20 ordinary shares of £ 0.0001 and every 20 non-voting ordinary shares of £ 0.0001 in the Company were consolidated into one ordinary share and one non-voting ordinary share of £ 0.002 . On February 9, 2021, the Company completed an IPO of 11,426,280 ADSs representing 11,426,280 ordinary shares with a nominal value of £ 0.002 . In addition to the ADSs sold in the IPO, the Company completed the concurrent sale of an additional 576,923 ADSs, representing 576,923 ordinary shares with a nominal value of £ 0.002 per ordinary share, at the initial offering price of $ 26.00 per ADS in a private placement to the Gates Foundation. The total net proceeds after deductions for underwriting discounts, commissions and other attributable offering expenses for the IPO and concurrent private placement were $ 286.9 million. Under the terms of the Company’s agreement with the Gates Foundation, the Company is required to develop, manufacture and commercialize soluble TCR bispecific therapeutic candidates targeted to mutually agreed neglected diseases, currently HIV, with the potential to treat people at an affordable price in developing countries. In the event of certain defaults by the Company under the agreement, which the Company considers to be within its control, the Gates Foundation has the right to sell, or require the Company to buy back, any of the shareholdings in the Company held by the Gates Foundation. In such an event, if within 12 months after such redemption or sale, the Company experiences a change in control at a valuation of more than 150 % of the valuation used for the redemption or the sale of the shares, the Company has agreed to pay the Gates Foundation compensation equal to the excess of what it would have received in such transaction if it still held its shares at the time of such change of control over what it received in the sale or redemption of its shares. F-22 Table of Contents 10. Share-based compensation At the time of the Company’s corporate reorganization and subsequent IPO in February 2021, previously awarded options were re-designated to reflect the equivalent number of options and exercise prices on the basis of the Company’s new shares. References in this note to options granted prior to the Company’s reorganization are made on this redesignated basis. Details of modifications in the year ended December 31, 2021 impacting the fair value of previously awarded options are provided further below under “Pre-IPO Grants”. The following table shows the total share-based compensation expense recorded in the Consolidated Statements of Operations and Comprehensive Loss (in thousands): 2023 2022 2021 R&D $ 6,467 $ 5,311 $ 5,365 Selling, general and administrative $ 26,002 $ 27,577 $ 43,529 Equity Incentive Plan (“EIP”) Under the Company’s EIP, the Company may grant market value options, share appreciation rights or restricted shares, restricted share units, performance share units and other share-based awards to the Company’s employees. The Company’s board members and consultants are eligible to receive awards under the Company’s non-employee sub-plan to the EIP. Awards may be granted at such times as the Company may determine, but will generally be granted annually following the end of the financial year. Awards vest at such times and as specified in the award agreement, typically being over a four-year period although the Company retains the discretion to provide for other vesting schedules. If the participant violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, the right of the participant to receive these shares on vesting shall terminate immediately. The Company maintains discretion over the type and terms of equity awards granted. All awards lapse on the tenth anniversary from the date of grant, and they are not subject to performance conditions or entitled to dividends. During the year ended December 31, 2023 and 2022, options over a total of 853,863 shares and 1,507,581 shares respectively were awarded under the Company’s EIP. Of the above awards in the year ended December 31, 2023, there were 43,380 options awarded to our non-executive directors, which vest on the first anniversary from the date of grant. In fiscal 2022, there were 66,972 n on-executive options awarded, 56,704 of which vested one year from the date of grant and 10,268 of which vest monthly over a three-year period. Pre-IPO Grants Prior to its IPO, the Company granted a limited number of options to employees and directors. These grants had varying terms, typically vesting over a four-year period with 25 % vesting at the end of the first year and the options lapsing on the tenth anniversary from the date of grant. Following the Company’s corporate reorganization in February 2021, previous options were re-designated to reflect an equivalent number of share options and exercise price on the basis of the Company’s new shares. There was no impact to the fair value of pre-IPO grants on redesignation, with the exception of 96,300 Growth shares awarded in previous periods and 2,911,260 options originally awarded in 2019. The 2019 awards were modified at the time of the Company’s reorganization through the removal of accelerated vesting conditions under certain circumstances. The incremental fair value granted was valued on a consistent basis to other awards made within the Company and was valued at $ 5.19 per share and was applied to those unvested awards as of the date of modification. Fair value inputs for the purposes of calculating the incremental fair value of the modification in January 2021 included an exercise price of $ 17.46 , a share price of $ 26.00 , an expected life of 3 years, expected volatility of 90 %, and a risk-free rate of - 0.13 %. As of December 31, 2023, there was $ 31.0 million of total unrecognized compensation cost related to stock options granted but not vested under the Company’s plans. That cost will be recognized over an expected remaining weighted-average period of 1.0 years. F-23 Table of Contents The number and weighted average exercise prices of share options are as follows: Number of shares issuable Number of share options (#) Weighted average exercise price ($) Average Remaining Contractual Term Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2021 4,551,359 $ 17.16 Awards granted 4,702,027 26.56 Awards exercised ( 76,762 ) 17.01 Awards forfeited ( 290,664 ) 31.24 Awards replaced with options 312,500 38.72 Outstanding at December 31, 2021 9,198,460 22.31 8.5 years $ 109,749 Awards granted 1,507,581 27.50 Awards exercised ( 492,163 ) 19.72 Awards forfeited ( 320,634 ) 26.41 Outstanding at December 31, 2022 9,893,244 23.10 7.9 years $ 336,120 Awards granted 853,863 62.57 Awards exercised ( 1,637,303 ) 20.93 Awards forfeited ( 141,922 ) 34.78 Outstanding at December 31, 2023 8,967,882 27.06 7.1 years $ 369,976 Exercisable at December 31, 2023 5,761,718 $ 22.26 6.7 years $ 265,412 The weighted average fair value of options granted in 2023 was $ 38.57 (2022: $ 16.93 ; 2021: $ 16.48 ). The weighted average share price at the date of exercise of the options during the year was $ 56.73 (2022: $ 46.17 ; 2021: $ 33.97 ). As of December 31, 2023 we have $ 0.5 million included in prepaid expenses and other current assets for exercises of options during the year. In the years ended December 31, 2023, 2022 and 2021 the total intrinsic value of stock options exercised was $ 58.4 million, $ 12.9 million and $ 1.3 million, respectively. The tax benefit arising on the exercise of stock options was $ 3.1 million, $ 2.6 million and $ 0.2 million for the years ended December 31, 2023, 2022 and 2021, respectively. Awards granted in the year ended December 31, 2023, 2022 and 2021, have been valued using the Black-Scholes option pricing model. The assumptions used in the models for share options granted during year ended December 31, 2023 2022 and 2021, are as follows: 2023 2022 2021 Share price at grant date $ 46.48 - $ 64.53 $ 24.66 - $ 46.86 $ 26.00 - $ 41.74 Exercise price $ 46.48 - $ 64.53 $ 24.66 - $ 46.86 $ 26.00 - $ 41.74 Expected volatility 66.7 % - 72.05 % 73.02 % - 87.81 % 83.88 % - 88.76 % Expected life (years) 5 years 4 years - 5 years 4 years Risk free rate 3.52 % - 4.75 % 1.12 % - 4.12 % - 0.05 % - 0.52 % Fair value $ 27.77 - $ 39.02 $ 15.10 - $ 29.41 $ 16.16 - $ 26.18 Share options are not entitled to dividends. 11. Basic and diluted net loss per share Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share amounts): 2023 2022 2021 Net loss for the year $ ( 55,287 ) $ ( 52,543 ) $ ( 180,029 ) Basic and diluted weighted average number of ordinary shares 48,888,975 45,714,923 42,488,579 Basic and diluted net loss per share $ ( 1.13 ) $ ( 1.15 ) $ ( 4.24 ) The potential shares through share options of 8,967,882 , 9,893,244 and 9,198,460 for the years ended December 31, 2023, 2022 and 2021, respectively, have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect. F-24 Table of Contents 12. Income taxes Net loss before income taxes is as follows (in thousands): 2023 2022 2021 United States $ 11,612 $ 7,509 $ 2,566 United Kingdom ( 76,866 ) ( 47,566 ) ( 182,816 ) Other worldwide 4,364 ( 826 ) 371 Net loss before income taxes $ ( 60,890 ) $ ( 40,883 ) $ ( 179,879 ) The components of income tax credit are as follows (in thousands): 2023 2022 2021 Current: United Kingdom $ — $ ( 12,420 ) $ ( 54 ) United States - Federal and State 215 ( 968 ) ( 146 ) Other worldwide ( 455 ) — ( 43 ) Total current tax $ ( 240 ) $ ( 13,388 ) ( 243 ) Deferred: United Kingdom $ — $ — $ — United States - Federal and State 5,873 1,694 93 Other worldwide ( 30 ) 34 — Total deferred tax $ 5,843 $ 1,728 $ 93 Total income tax credit (expense) $ 5,603 $ ( 11,660 ) $ ( 150 ) The tax effects of temporary differences and carryforwards that give rise to deferred tax assets and liabilities were as follows (in thousands): 2023 2022 Deferred tax assets Net losses $ 74,916 $ 73,059 Fixed assets 4,286 5,241 R&D credits 5,745 6,166 Corporate interest restriction — 731 Stock based compensation 9,795 6,329 Other deferred tax assets 511 875 Total deferred tax assets $ 95,253 $ 92,401 Deferred tax liabilities Other deferred tax liabilities ( 1,154 ) ( 844 ) Total deferred tax liabilities $ ( 1,154 ) $ ( 844 ) Valuation allowance ( 83,126 ) ( 86,436 ) Net deferred tax assets $ 10,973 $ 5,121 The movements in the deferred tax asset valuation allowances are as follows (in thousands): 2023 2022 Valuation allowance as of January 1, $ ( 86,436 ) $ ( 87,867 ) Decrease (Increase) in valuation allowance through net loss 7,573 ( 7,680 ) Foreign currency translation adjustments ( 4,263 ) 9,111 Valuation allowance as of December 31, $ ( 83,126 ) $ ( 86,436 ) F-25 Table of Contents Reconciliation of the U.K. statutory income tax rate, the income tax rate of the country of domicile of the Company, to the Company’s effective income tax rate is as follows (in percentages): 2023 2022 2021 U.K. statutory income tax rate 23.5 % 19.0 % 19.0 % Non-deductible expenses ( 1.1 )% ( 20.7 )% ( 9.8 )% Above the line credit not taxable ( 2.9 )% 7.3 % 1.4 % Additional deduction for R&D expenditure — 50.6 % 9.4 % Surrender of tax losses for R&D tax credit refund — ( 9.6 )% ( 9.4 )% R&D expenditure credits 5.3 % ( 28.0 )% 0.8 % Share based payments ( 3.0 )% — — State taxes 0.1 % 1.3 % — Foreign rate differential 1.3 % ( 0.5 )% ( 0.1 )% Prior period adjustments 0.5 % 0.4 % ( 0.3 )% Leases — ( 0.4 )% ( 0.4 )% Change in valuation allowances ( 14.5 )% ( 47.9 )% ( 10.7 )% Effective income tax rate 9.2 % ( 28.5 )% ( 0.1 )% On May 24, 2021, the U.K. 2021 Finance Bill was substantively enacted and subsequently received Royal Assent on June 10, 2021. Under this bill, the rate of U.K. corporation tax has increased to 25% in 2023, with lower rates and tapered relief applied to companies with profits below $ 2.5 million. As of December 31, 2023, the Company’s net operating loss carryforwards in the United Kingdom totaled $ 286 million. As of December 31, 2023, the Company has U.S. R&D credits totaling $ 5.7 million, of which, $ 5.3 million relates to federal tax credits. U.K. tax credit carryforwards can be carried forward indefinitely to be offset against future tax liabilities of the company. Non-U.K. net operating loss carryforwards can be carried forward indefinitely. U.S. tax credit carryforwards can be carried forward for 20 years to be offset against future tax liabilities, subject to a minimum tax payment of 25% of the tax charge. A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The majority of the Company’s deferred tax assets relate to net operating loss and R&D carryforwards that can only be realized if the Company is profitable in future periods. Accordingly, the Company has provided a valuation allowance against a substantial amount of the net deferred tax assets due to uncertainties as to their ultimate realization. The Company operates in multiple jurisdictions with complex tax and regulatory environment and our tax returns are periodically audited or subjected to review by tax authorities. The following table summarizes tax years that remain subject to examination by tax jurisdiction as of December 31, 2023: Jurisdiction Open Tax Years Based on Originally Filed Returns United Kingdom 2021 - 2022 United States 2020 - 2022 The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of December 31, 2023 and 2022, the Company has no t recorded any provision for uncertain tax positions. F-26 Table of Contents 13. Commitments and contingencies Lease Commitments See “Leases,” for the maturities of operating lease liabilities as of December 31, 2023. Manufacturing Commitments The Company enters into a number of manufacturing commitments for the future purchase of materials and contract manufacturing services. While the majority of such contracts can be cancelled on reasonable notice, due to the significant ongoing expenditure associated with the Company’s programs, including IMC-F106C (PRAME), the Company estimates it has noncancellable commitments in relation to the development and supply of product candidates totaling, $ 13.1 million, which are expected to be paid in 2024 Legal Proceedings The Company is not currently a party to any material legal proceedings. 14. Subsequent events On February 2, 2024, the Company completed a private offering of $ 402.5 million aggregate principal amount of 2.50 % Convertible Senior Notes due 2030 (Notes). The Company’s net proceeds from the offering of the Notes were $ 389.3 million, after deducting the initial purchasers’ discounts and commissions and the estimated offering expenses. The Notes are senior, unsecured obligations of the Company and will mature on February 1, 2030 , unless earlier converted, redeemed or repurchased. The Notes will accrue interest payable semi-annually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024, at a rate of 2.50 % per year. In February 2024, the Company entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to investigate it’s ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb’s nivolumab, in first-line advanced cutaneous melanoma. Under the terms of the collaboration, the Company will sponsor and fund the registrational Phase 3 clinical trial of IMC-F106C in combination with nivolumab in first-line advanced cutaneous melanoma (PRISM-MEL-301), and Bristol Myers Squibb will provide nivolumab . F-27